Cybin Inc. (NYSE:CYBN - Free Report) - Investment analysts at HC Wainwright decreased their FY2029 earnings per share (EPS) estimates for Cybin in a research report issued on Monday, January 27th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of $8.87 for the year, down from their prior forecast of $9.57. HC Wainwright currently has a "Buy" rating and a $190.00 price target on the stock. The consensus estimate for Cybin's current full-year earnings is ($4.83) per share.
Separately, Canaccord Genuity Group lowered their price target on Cybin from $96.00 to $86.00 and set a "buy" rating for the company in a report on Thursday, November 14th.
Check Out Our Latest Stock Analysis on CYBN
Cybin Price Performance
Cybin stock traded down $0.07 during trading on Wednesday, hitting $9.91. The company's stock had a trading volume of 171,025 shares, compared to its average volume of 176,659. The stock has a fifty day moving average price of $9.76. Cybin has a 1-year low of $6.50 and a 1-year high of $19.85. The stock has a market capitalization of $199.32 million, a PE ratio of -1.49 and a beta of 0.44.
Institutional Trading of Cybin
A hedge fund recently bought a new stake in Cybin stock. Sanctuary Advisors LLC purchased a new stake in shares of Cybin Inc. (NYSE:CYBN - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 131,252 shares of the company's stock, valued at approximately $36,000. Institutional investors own 17.94% of the company's stock.
About Cybin
(
Get Free Report)
Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds.
Read More
Before you consider Cybin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cybin wasn't on the list.
While Cybin currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
